Want to see HK:1548 full AI Analyst Report?
Total Valuation
Genscript Biotech has a market cap or net worth of HK$29.63B. The enterprise value is HK$3.23B.
Market CapHK$29.63B
Enterprise ValueHK$3.23B
Share Statistics
Genscript Biotech has 2,188,547,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,188,547,400
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Genscript Biotech’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is 5.54%.
Return on Equity (ROE)-0.13
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)5.54%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee172.33K
Profits Per Employee-84.51K
Employee Count5,568
Asset Turnover0.20
Inventory Turnover10.26
Valuation Ratios
The current PE Ratio of Genscript Biotech is ―. Genscript Biotech’s PEG ratio is -0.00903.
PE Ratio―
PS Ratio3.60
PB Ratio0.87
Price to Fair Value0.87
Price to FCF14.31
Price to Operating Cash Flow11.23
PEG Ratio-0.00903
Income Statement
In the last 12 months, Genscript Biotech had revenue of 959.53M and earned -532.83M in profits. Earnings per share was -0.25.
Revenue959.53M
Gross Profit553.20M
Operating Income255.25M
Pretax Income-470.53M
Net Income-532.83M
EBITDA317.61M
Earnings Per Share (EPS)-0.25
Cash Flow
In the last 12 months, operating cash flow was 325.52M and capital expenditures -83.84M, giving a free cash flow of 241.69M billion.
Operating Cash Flow325.52M
Free Cash Flow241.69M
Free Cash Flow per Share0.11
Dividends & Yields
Genscript Biotech pays an annual dividend of HK$0.012, resulting in a dividend yield of ―
Dividend Per ShareHK$0.012
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.05
52-Week Price Change-9.87%
50-Day Moving Average13.13
200-Day Moving Average13.89
Relative Strength Index (RSI)58.79
Average Volume (3m)11.61M
Important Dates
Genscript Biotech upcoming earnings date is Aug 17, 2026, TBA (Confirmed).
Last Earnings DateMar 16, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Genscript Biotech as a current ratio of 1.47, with Debt / Equity ratio of 6.54%
Current Ratio1.47
Quick Ratio1.41
Debt to Market Cap0.16
Net Debt to EBITDA0.27
Interest Coverage Ratio14.74
Taxes
In the past 12 months, Genscript Biotech has paid 61.87M in taxes.
Income Tax61.87M
Effective Tax Rate-0.13
Enterprise Valuation
Genscript Biotech EV to EBITDA ratio is 11.16, with an EV/FCF ratio of 14.66.
EV to Sales3.69
EV to EBITDA11.16
EV to Free Cash Flow14.66
EV to Operating Cash Flow10.88
Balance Sheet
Genscript Biotech has HK$843.01M in cash and marketable securities with HK$258.84M in debt, giving a net cash position of HK$584.17M billion.
Cash & Marketable SecuritiesHK$843.01M
Total DebtHK$258.84M
Net CashHK$584.17M
Net Cash Per ShareHK$0.27
Tangible Book Value Per ShareHK$1.83
Margins
Gross margin is 57.65%, with operating margin of 26.60%, and net profit margin of -55.53%.
Gross Margin57.65%
Operating Margin26.60%
Pretax Margin-49.04%
Net Profit Margin-55.53%
EBITDA Margin33.10%
EBIT Margin26.60%
Analyst Forecast
The average price target for Genscript Biotech is HK$25.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$25.57
Price Target Upside85.83% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast60.96%
EPS Growth Forecast-117.64%